Message from Boyce Burge on Oct 9 1996 2:29PM EST
Biotech Newsletters in general
are disappointing... including MTSL, whose recommendations and rational seem to
me way off the mark these days... (Somatogen??..really!!)
/////////////////
(sorry for the strange formating.... I'll figure out how to quote)
Yup. Sturza is, IMO, the worst of those that are discussed most, and CTSL is a close second. While I don't think MTSL is very good, I do think it's the best. :-) McCamant at least finds some decent issues early. However, he (1) believes derivative stuff from company management without doing sufficient investigation of what's happening at the bench, and (2) doesn't have a clue with respect to the technologies involved. He was a raving mainiac over XOMA at 32 a few years ago, doing nothing other than calling management to ask them if the company was good. I can picture management saying "no, we stink". :-)
//////////////////////////////
Also, I've had good experiences with the genome companies... INCY, HGSI,
AFFX, SQNA... the impact of sequencing and computer analysis on medicine will
be very BIG... possibly I'm a little early, but its inevitable.
/////////////////
The Genetics Institute deal with CHIR and GNE is interesting for secreted proteins. Yup, I bailed from INCY and SQNA eariler this year after their big run-up. I planned on buying them again after they corrected, but they never hit my targets. Now I'm feeling out in the cold. :-) I'm trying to sneak in, however, and I bought PBIO for its genomics play.
John De Castro, who contributes (I think) to the NTII thread here at SI, is a real NTII freak. Bug him if you want more info. You have great taste in biotechs.
Cheers! Rick |
